Fms-like Tyrosine Kinase 3 Receptor D835Y Mutant (FLT3 D835Y)

The Fms-like tyrosine kinase 3 (FLT3) receptor D835Y mutant is a gain-of-function mutation where aspartic acid at position 835 is replaced by tyrosine within the tyrosine kinase domain activation loop. This results in constitutive activation of FLT3, independent of ligand binding, leading to uncontrolled cell proliferation and leukemogenesis. It is a significant driver mutation in acute myeloid leukemia (AML) and is associated with poor prognosis. Therapeutic strategies involve small molecule inhibitors targeting FLT3, as well as emerging immunotherapeutic approaches targeting the FLT3-D835Y neoantigen.

Other names

FLT3-D835YCD135 D835YFLT3 tyrosine kinase domain mutantFLT3 activation loop mutant

Inhibition of FLT3 kinase activity, targeting downstream signaling pathways (STAT5, ERK1/2, AKT). Some immunotherapies target FLT3-D835Y neoantigen.